Evaluation of Organ Stiffness and Cardiac Function in Myelofibrosis Patients Treated with Ruxolitinib

Cancer research · Myelofibrosis

Ruxolitinib demonstrated its greatest benefit at 6 months, significantly reducing organ size, stiffness, and symptom burden, followed by cardiovascular improvement and normalization of sPAP by 12 months.

The study prospectively evaluated changes in spleen and liver stiffness and cardiac function in 30 myelofibrosis patients receiving ruxolitinib at baseline, 6, and 12 months. Significant reductions in organ size and stiffness were observed at 6 months, with continued stabilization and improvement in systolic pulmonary artery pressure and NT‑proBNP at 12 months.

These findings highlight the early and sustained benefit of ruxolitinib in decreasing extramedullary organ fibrosis and improving cardiac parameters, informing clinical management of myelofibrosis.

Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.

Original source

Related signals